Trial Profile
A 26-week, Randomized, Double Blind, Parallel-group Multicenter Study to Assess the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Glycopyrrolate/indacaterol (Primary) ; Salmeterol/fluticasone propionate; Tiotropium bromide
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms SUNSET
- Sponsors Novartis; Novartis Pharmaceuticals
- 23 May 2018 Results assessing the effects and safety of ICS withdrawal in COPD patients on long-term triple therapy who are not frequent exacerbators presented at the 114th International Conference of the American Thoracic Society
- 20 May 2018 Primary endpoint (Post-dose trough FEV1-non-inferiority of indacaterol/glycopyrronium versus tiotropium plus salmeterol/fluticasone) has not been met, according to results published in the American Journal of Respiratory and Critical Care Medicine.
- 20 May 2018 Results published in the American Journal of Respiratory and Critical Care Medicine.